Click a keyword to view all the abstracts on this site tagged with that keyword.
- 18FDG PET/CT scan
- 25 OH D Vitamin insufficiency
- 25-hydroxyvitamin D
- 25-hydroxyvitamin D and rheumatoid arthritis (RA)
- 25-hydroxyvitamin D and Vitamin D
- 3D model
- 3D model and arthritis
- 5-HT
- A3 Adenosine receptor and gout
- AA-amyloidosis
- AA-amyloidosis and familial Mediterranean fever
- Abatacept
- Abatacept and adult-onset Still's disease
- abatacept and anti-citrullinated protein/peptide antibodies (ACPA)
- abatacept and anti-TNF therapy
- abatacept and biomarkers
- Abatacept and body mass
- Abatacept and health care cost
- abatacept and histopathologic
- Abatacept and juvenile idiopathic arthritis (JIA)
- Abatacept and macrophages
- abatacept and magnetic resonance imaging (MRI)
- abatacept and monocytes
- abatacept and patient-reported outcome measures
- abatacept and remission
- abatacept and rheumatoid arthritis
- Abatacept and rheumatoid arthritis (RA)
- abatacept and rituximab
- abatacept and treatment
- Abatacept and tuberculosis
- abatacept and ultrasonography
- Abstracts
- academic
- academics
- Access to care
- access to care and health disparities
- access to care and high risk
- Access to care and inflammatory arthritis
- Access to care and lupus nephritis
- access to care and medication
- access to care and physical therapy
- access to care and population studies
- Access to care and primary care
- Access to care and quality measures
- Access to care and quality of care
- access to care and remission
- Access to care and rheumatologic disease
- Access to care and systemic lupus erythematosus (SLE)
- accommodation
- Accreditation
- ACE-inhibitors
- ACPA
- ACPA and cardiovascular disease
- ACPA and lung
- ACPA and osteoclastogenesis
- ACPA and palindromic rheumatism
- ACPA and Periodontitis
- ACPA and psoriatic arthritis
- ACPA and RANK/RANKL pathway
- ACPA and rheumatoid arthritis (RA)
- ACR
- ACR and rheumatoid arthritis (RA)
- Activation triggers
- activation triggers and dendritic cells
- activities of daily living (ADL)
- activities of daily living (ADL) and myositis
- activities of daily living (ADL) and systemic sclerosis
- Activity score
- Activity score and ankylosing spondylitis (AS)
- activity score and anti-dsDNA
- activity score and assessment
- activity score and biomarkers
- activity score and classification criteria
- activity score and patient outcomes
- Activity score and patient questionnaires
- Activity score and polychondritis
- activity score and polymyalgia rheumatica
- activity score and prolactin
- Activity score and psoriatic arthritis
- Activity score and rheumatoid arthritis (RA)
- Activity score and systemic lupus erythematosus (SLE)
- activity score and systemic sclerosis
- Activity score and total joint replacement
- activity score and treatment
- Activity score and uveitis
- acupressure and clinical trials
- acupuncture and pediatrics
- Acute-phase reactants
- Acute-phase reactants and ankylosing spondylitis (AS)
- acute-phase reactants and familial Mediterranean fever
- acute-phase reactants and rheumatoid arthritis (RA)
- Adalimumab
- adalimumab and ankylosing spondylitis (AS)
- adalimumab and anti-CCP antibodies
- adalimumab and anti-citrullinated protein/peptide antibodies (ACPA)
- Adalimumab and biosimilars
- adalimumab and economics
- Adalimumab and health care cost
- adalimumab and inflammatory arthritis
- Adalimumab and inflammatory bowel disease (IBD)
- adalimumab and interleukins (IL)
- Adalimumab and juvenile arthritis
- Adalimumab and juvenile idiopathic arthritis (JIA)
- adalimumab and juvenile idiopathic arthritis-enthesitis (ERA)
- Adalimumab and juvenile spondylarthropathy
- adalimumab and matrix metalloproteinase (MMP)
- adalimumab and messenger RNA (mRNA)
- adalimumab and methotrexate (MTX)
- Adalimumab and psoriatic arthritis
- Adalimumab and rheumatoid arthritis
- adalimumab and rheumatoid arthritis (RA)
- Adalimumab and spondylarthritis
- Adalimumab and spondylarthropathy
- adalimumab and support
- Adalimumab and uveitis
- adaptive immunity
- adaptive immunity and cutaneous lupus erythematosus
- Adenosine receptors
- Adenosine receptors and collagen
- adenosine receptors and endothelial cells
- adenosine receptors and osteoblasts
- Adenosine receptors and osteoclastogenesis
- adenosine receptors and prosthesis
- Adenosine receptors and rheumatoid arthritis (RA)
- adenosine receptors and salivary hypofunction
- Adenosine receptors and scleroderma
- Adhesion molecules
- adhesion molecules and epigenetics
- Adhesion molecules and inflammation
- adhesion molecules and neutrophils
- adhesion molecules and rheumatoid arthritis (RA)
- adhesion molecules and signal transduction
- adhesive capsulitis
- Adipocytokines
- Adipocytokines and rheumatoid arthritis (RA)
- Adipocytokines and systemic lupus erythematosus (SLE)
- Adipocytokines and systemic sclerosis
- Adipokines
- Adipokines and osteoarthritis
- adipokines and rheumatoid arthritis
- Adipokines and rheumatoid arthritis (RA)
- adipose tissue
- adipose tissue and bone density
- adipose tissue and sarcopenia
- adjuvant arthritis
- adjuvant arthritis and osteoclasts
- administrative databases
- administrative databases and evaluation
- Administrative databases and gout
- administrative databases and pediatric rheumatology
- administrative databases and rheumatoid arthritis
- Administrative databases and rheumatoid arthritis (RA)
- administrative databases and spondylarthritis
- administrative databases and systemic lupus erythematosus (SLE)
- Adolescence
- Adolescence and Transition
- Adolescent
- Adolescent patients
- adolescent patients and pediatric rheumatology
- adolescent patients and quality improvement
- adolescent patients and social media
- Adult-onset Still's disease
- adult-onset Still's disease and apoptosis
- adult-onset Still's disease and canakinumab
- adult-onset Still's disease and chemokines
- adult-onset Still's disease and familial Mediterranean fever
- adult-onset Still's disease and interleukins (IL)
- adult-onset Still's disease and macrophage activation syndrome
- Adult-onset Still's disease and malignancy
- adult-onset Still's disease and natural killer (NK) cells
- Adult-onset Still's disease and tocilizumab
- Advanced glycation end-products (AGEs)
- Advanced glycation end-products (AGEs) and systemic sclerosis
- Adverse events
- Adverse events and anti-TNF therapy
- adverse events and arthritis
- adverse events and autoimmune diseases
- adverse events and azathioprine
- adverse events and cancer treatments
- adverse events and combination therapies
- adverse events and data analysis
- adverse events and heart disease
- adverse events and infection
- adverse events and meta-analysis
- adverse events and osteoarthritis
- adverse events and polymyalgia rheumatica
- adverse events and rheumatic disease
- adverse events and rheumatoid arthritis
- adverse events and rheumatoid arthritis (RA)
- Adverse events and systemic lupus erythematosus (SLE)
- Advocacy
- Aerobic
- African-Americans
- African-Americans and rheumatoid arthritis (RA)
- African-Americans and self-management
- African-Americans and systemic lupus erythematosus (SLE)
- African-Americans and systemic sclerosis
- African-Americans and total joint replacement
- African-Americans and vasculitis
- Aging